ARS Pharma targets cash flow breakeven by end of 2027 as it cuts cash-based SG&A and R&D to $100M-$110M in H2 2026

XBP Global targets $65M-$75M in annualized efficiencies while revenue per employee approaches $100,000 by year-end

Aveanna hits 52-week high after Q2 beat, guidance hike

Eton Pharmaceuticals forecasts 2026 revenue to exceed $145M while targeting adjusted EBITDA margin above 35%

Asian stocks trade mixed as U.S. inflation cools; Strait of Hormuz risks weigh